Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
They have filed the OTCQB certification every year since 2015 or so. It's a legitimacy move to help keep red flag stop signs off the ticker
FWIW, it did break 0.40 yesterday by hitting 0.4028 :)
But man, you're spot on today so far...keeps hitting 0.40 ceiling and not wanting to break.
My thesis has not changed. Short term BUCC, long term psychedelics (aka minimal downside risk). I will be holding my full position
I posted my takeaways from the presentation today on StockTwits, thought some of yall would be interested:
http://stocktwits.com/ellerk88/message/315553368
All of RVV's annual meetings from year's past have used the 'Annual and Special Shareholder Meeting' verbiage. I think some are looking way too much into this.
Of course I always have hope there is something big, but also remember this meeting is typically held in November/December. This is late.
That has been up for quite some time and im not even sure anyone has been able to find who published that target or when
*sigh* .... let's go ...
Thank you thank you THANK YOU!!!
Tired of the schmucks wanting bogus, price faking PR... we want to be a real company doing real things. Stop whining about them acting like a real one.
Not a single study has shown masks to provide any efficacy in mitigating community spread. The current publications are for medical masks in medical environments with proper fit, training, and mask rotation.
In addition, the natural experiment of counties with mask mandate/no mandate, as well as states with mask mandate/no mandate show similar outcomes.
Cloth masks were a mechanistic possibility... but thats it.
On the heels of hotmeat's reply, he's spot on. A virus that has a low fatality rate, coupled with the fact that nearly all deaths have been people 65+ and/or comorbidities. The data is clear here and the emotional responses need to take a step back into reality.
The virus is real, but so is the data. We all make calculated risk/benefit decisions. Some prefer to use data.
I am for this, preferably getting there in an organic fashion and not having to perform a huge R/S.
NASDAQ requires $4 minimum listing price. The $2 and $3 exemptions for listing have additional requirements, of which RVVTF does not meet currently (Page 10 - chart and footnote)
https://listingcenter.nasdaq.com/assets/initialguide.pdf
2.39M in stock-based compensation for MF in the 6 months ended December 31, 2020 in addition to 120K in cash ...
For 6 months worth of work, 315M outstanding shares, and a 125M market cap: $19K ... 40K shares ... it is most definitely a measly drop in a giant bucket. I'm 400K shares strong and heavily bullish for all reasons considered, but this attempt at signaling an undervalued company was extremely weak
Obviously this has cleared up the Q1, Q2 designations from the prospectus. Some here need to chill out with the ALL CAPS 'holier than thou' next time.
Lots in the next few weeks expected. Shareholder agenda release within 2 weeks of March 1 passing, interim complete by March 31 (mind you it doesn't say 'news release'), and April 5 meeting.
April is also in Q2 of 2021, let's not discredit that.
It is also of note that this provides some much needed clarification on the 'Q' referencing from the previous MD&A and prospectus confusion. What is favorable here is the company has estimated that interim results should be complete in the next few weeks (mistake that there are two line-items with the same interim results suggestion? - Maybe a 210 and a 400 interim?)
With regard to your herd immunity suggestion, frankly, it's absurd given every PR release by international and national organizations (and the Fauci himself) saying even 2022 will have problems. There will be treatments needed, and the provisional patent filing covers bucillamine as a treatment for 'infectious diseases', not just COVID itself. I think buc still has a long way to go even outside the COVID space.
Or ya know... just take the 0.47 and apply the approximate conversion rate of 1.22
0.47 x 1.22 = 0.5734
Seems like a fair approximation originally.
Fair idea in theory, but the warrants are risk-free. Equity units through the offering were purchased at a discount to the market price ... sure, they want price to go up for warrant execution - it's free money... but there's no risk for those warrants
The annual/special meeting agenda should be posted a few days (clarification below) after March 1 according to the previous notice filed - so we can see if there is anything special coming up other than the standard annual hooplah. March 1 is the date of record for voting shareholders and beneficiary ownership. But the agenda in year's past has typically come out a few days after that date of record.
The actual meeting is scheduled for April 5.
Correction: the agenda in year's past was posted anywhere from 9-15 days after the date of shareholder record. So we might not see that agenda until March 10-15 or so.
I don't disagree. Flippers do hold overnight and the timing of the other comment was during day yesterday. Those sellers yesterday made off without losing this morning. That is an indisputable fact. So the poster who brings up the I TOLD YOU SO moment has short term egg on their face. Nice shower and a shave will bode well long term of course
I didn't say the buy wasn't legitimate. I made a reply to a supposed 'haha' moment... which it wasn't. At the open, the penny flippers actually had the laugh.
Long term, of course it should generate extreme value for the psilocybin arm. Short term, not so much.
Many of you are quick to draw and even quicker to be offended. Chill out when challenged and accept that there are others out here who do have the slightest clue.
Dissenting opinion or skepticism is good for getting out of your echo chamber. In fact, good discussion with dissent should only reinforce your beliefs if they are on truly solid ground.
I mean, we knew this was coming. Why would it be a major catalyst other than it actually closing with final figures? We trade some equity/cash for a decent asset. Not sure the market is going to truly value that psilocybin IP that heavily right now.
Please go check the OTC Markets Trading Hours page. There is a broker PM where some retail traders are allowed to make moves.
There is an OTC LinkATS that some brokers have access to. There is def a small PM and is posted on OTC Markets Trading Hours page
Thank God. I'll take your share dump from you, ya impatient weasel.
Phase 3 and you haven't even been here a couple months? Laughable fool
It's not BS to remind shareholders and the market that you are a player in the industry that is getting huge attention right now. This isn't pumping, this is introducing liquidity and attention.
Put your baby back bias to bed and get out here with a real investor attitude.
Eh, I think we are all a bit confused by the seeming inconsistency in the prospectus.
One portion looks to be from MD&A and suggests 200 patients completed by Q2-2021. But then for the 'Proceeds of the Offering' section, we see a bit about 210 by end of Q1-2021 and 400 by Q2-2021.
Now... the question is are we being consistent about dates and reference to calendar/fiscal year? We all believed the primary dosage on the 210 was complete or would be compete by end of December seeing as we were 'on pace' (MFs words in Dec 23 release).
Inconsistencies in interpretation are what is causing this hubbub.
See but that doesn't reconcile with the statements under the 'Proceeds from the Offering' section.
That section says it's estimated 210 interim is done in Q1-2021 and 400 interim done in Q2-2021.... we are recruiting patients so slowly! Why?!?!
Lots of forms added to SEDAR. Prospectus, legal counsel letters, auditor letters, notice of material contract, etc.
Offering is closing!!!
When FDA verbiage is used to describe a drug, I expect that drug to have been through the formal process. I addressed the Phase 2 crossover allowance due to NAC efficacy on ACE inhibition in another comment.
Words matter, people. As excited as you can get about an equity, it's still disingenuous to spread misinformation. Revive has too many good things in place for some stretched information to attack validity. This group is too in tune for that PINK BS. Despite RVVTF still sitting on PINKs, We want them to be a big dog - hold yourselves to higher standards with your diligence.
BUCC is bucillamine... the primary drug focus for RVVTF right now.
It certainly looks that way since BUCC didn't have phase 1 and phase 2 trials for COVID specifically. But that's also why the scientific rationale for BUCC use against COVID-19 is in every PR.
Previous phase 2 trials for BUCC were for gout flares and cystinuria. For cystinuria specifically, BUCC was shown to reduce cystine as a binding agent. Given the research last summer (N-acetyl-cysteine), the FDA could viably move BUCC (a thiol now shown to be more potent than other NACs) into a COVID-19 Phase 3 trial due to its potential to reduce those ACE receptors
Of course - I love everything the company is doing and it's primed for great success in the future ... even moreso with positive phase 3 results.
My only clarification was to say that BUCC is not a 'Fast Track' designated drug. Where the FDA might still be more involved than a typical phase 3 trial, we do not have a formal 'Fast Track' designation from the regulatory body.
Again, I am super long on this thing and hope to make millions off of a BUCC buyout and subsequent pyschedelic run - live changing company here with the right catalysts at the right time. But let's not dilute the good things that ARE in line for the company currently with misinformation.
I am bullish with the company - but I have seen many people (forums) claim that BUCC has 'Fast Track' status with the FDA, which is simply untrue.
I am well aware of the timeline of the design and the FDA's involvement given the COVID circumstances. I just wanted to be sure that the Fast Track designation was not misconstrued.
No, it's not. Asking for Fast Track designation at this point is a waste of time. Fast Track is designed for phase 3 and prior. We never formally received Fast Track from the FDA. Remdesivir was the only covid 19 trial approved for Fast Track status in 2020
Where have we been given Fast Track status? Every PR associated uses the words 'fast track' due to MF's quote from August... but there is no record of the FDA granting BUCC formal Fast Track status
Just cleaning financials/reporting so big boy bamker deal can close
I'm giddy!! Too many things happening in the next month or two. And love the psychedelic long play
From what I've seen in my experiences with investors and executives, e-mails sent to CEOs with a lot of emotion and frustration are generally moved to 'File 13' as nothing good comes out of replying.
In addition, we have a $20M CAD offering with a big investment bank yet to be finalized and a double-blind phase 3 trial. Why risk saying anything with that sort of cash on the table?
Are you new at this?
Notice of meeting posted on SEDAR
Notice with agenda listed for March 1, meeting date is April 5.
This is most likely the annual meeting that was not held in December 2020, but might have some big time items on it.
Ask RDGL investors how tweeting 'helped' out so much recently....
Asking for tweets is juvenile. We want formal PRs and business action. The trial is still moving until told otherwise. That's a good sign. Diamond hands for RVVTF...
I won't question your diligence - Just wanted to make sure people still understand the positive upside here despite the unexpected timeline.
And I don't pit two companies against each other to determine alpha return when they are in different phases of different industries - that's not a viable strategy and will lead one to insanity as there are 100+%ers everyday that could be placed into conversation